Premium
A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide‐containing regimens
Author(s) -
Sanchez Larysa,
Vesole David H.,
Richter Joshua R.,
Biran Noa,
Bilotti Elizabeth,
McBride Laura,
Anand Palka,
Ivanovski Kristin,
Siegel David S.
Publication year - 2017
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.14429
Subject(s) - lenalidomide , medicine , regimen , vorinostat , dexamethasone , multiple myeloma , neutropenia , gastroenterology , refractory (planetary science) , population , thalidomide , progressive disease , oncology , pharmacology , surgery , chemotherapy , histone deacetylase , biology , biochemistry , environmental health , astrobiology , gene , histone
Summary Clinical trials of vorinostat, a Class I/II histone deacetylase inhibitor, in combination with proteasome inhibitors and immunomodulatory agents have shown activity in relapsed/refractory multiple myeloma. This phase IIb, open‐label, single‐institution study evaluated the efficacy of vorinostat in combination with lenalidomide and dexamethasone in lenalidomide‐refractory patients. Patients were considered lenalidomide‐refractory if they had no clinical response (